The effect of tolvaptan on kidney function in patients with autosomal dominant polycystic kidney disease

被引：1
|
作者：
Kawada, Tomoyuki [1 ]
机构：
[1] Nippon Med Sch, Dept Hyg & Publ Hlth, Bunkyo Ku, 1-1-5 Sendagi, Tokyo 1138602, Japan
来源：
CLINICAL AND EXPERIMENTAL NEPHROLOGY | 2016年 / 20卷 / 01期
关键词：
Estimated glomerular filtration rate; Autosomal dominant polycystic kidney disease; Tolvaptan; Validity;
D O I：
10.1007/s10157-015-1134-y
中图分类号：
R5 [内科学]; R69 [泌尿科学（泌尿生殖系疾病）];
学科分类号：
1002 ; 100201 ;
摘要：
[No abstract available]
引用
收藏
页码：147 / 148
页数：2
相关论文
共 50 条
  • [31] Creatine Kinase Elevation in Autosomal Dominant Polycystic Kidney Disease Patients on Tolvaptan Treatment
    Rodriguez-Espinosa, Diana
    Jesus Broseta, Jose
    Bastida, Carla
    Isabel Alvarez-Mora, Maria
    Nicolau, Carlos
    Alvarez, Cristina
    Agraz-Pamplona, Irene
    Sanchez-Baya, Maya
    Furlano, Monica
    Ruiz, Cesar
    Quintana, Luis F.
    Pineiro, Gaston J.
    Poch, Esteban
    Torra-Balcells, Roser
    Blasco, Miquel
    NEPHRON, 2023, 147 (3-4) : 152 - 157
  • [32] Effect of pravastatin on kidney function and urinary protein excretion in autosomal dominant polycystic kidney disease
    Fassett, Robert G.
    Coombes, Jeff S.
    Packham, David
    Fairley, Kenneth F.
    Kincaid-Smith, Priscilla
    SCANDINAVIAN JOURNAL OF UROLOGY AND NEPHROLOGY, 2010, 44 (01): : 56 - 61
  • [33] Tolvaptan in the treatment of autosomal dominant polycystic kidney disease: patient selection and special considerations
    Sans-Atxer, Laia
    Joly, Dominique
    INTERNATIONAL JOURNAL OF NEPHROLOGY AND RENOVASCULAR DISEASE, 2018, 11 : 41 - 51
  • [34] Comparison of Different Selection Strategies for Tolvaptan Eligibility among Autosomal Dominant Polycystic Kidney Disease Patients
    Wulfmeyer, Vera C.
    Auber, Bernd
    Haller, Hermann
    Schmitt, Roland
    AMERICAN JOURNAL OF NEPHROLOGY, 2019, 50 (04) : 281 - 290
  • [35] A Case Report of Tuberous Sclerosis and Autosomal Dominant Polycystic Kidney Disease in the Era of Tolvaptan
    Guerra-Torres, Xavier E.
    CURRENT REVIEWS IN CLINICAL AND EXPERIMENTAL PHARMACOLOGY, 2023, 18 (03) : 284 - 290
  • [36] Short-term Effects of Tolvaptan in Individuals With Autosomal Dominant Polycystic Kidney Disease at Various Levels of Kidney Function
    Boertien, Wendy E.
    Meijer, Esther
    de Jong, Paul E.
    ter Horst, Gert J.
    Renken, Remco J.
    van der Jagt, Eric J.
    Kappert, Peter
    Ouyang, John
    Engels, Gerwin E.
    van Oeveren, Willem
    Struck, Joachim
    Czerwiec, Frank S.
    Oberdhan, Dorothee
    Krasa, Holly B.
    Gansevoort, Ron T.
    AMERICAN JOURNAL OF KIDNEY DISEASES, 2015, 65 (06) : 833 - 841
  • [37] Acute Kidney Injury Due to Nephrolithiasis in Autosomal Dominant Polycystic Kidney Disease Treated With Tolvaptan: A Case Report
    Shima, Hisato
    Nishitani, Masaaki
    Izaki, Hirofumi
    Minakuchi, Jun
    CUREUS JOURNAL OF MEDICAL SCIENCE, 2024, 16 (06)
  • [38] Long-Term Administration of Tolvaptan in Autosomal Dominant Polycystic Kidney Disease
    Edwards, Marie E.
    Chebib, Fouad T.
    Irazabal, Maria V.
    Ofstie, Troy G.
    Bungum, Lisa A.
    Metzger, Andrew J.
    Senum, Sarah R.
    Hogan, Marie C.
    El-Zoghby, Ziad M.
    Kline, Timothy L.
    Harris, Peter C.
    Czerwiec, Frank S.
    Torres, Vicente E.
    CLINICAL JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2018, 13 (08): : 1153 - 1161
  • [39] Effect of simvastatin on renal function in autosomal dominant polycystic kidney disease
    van Dijk, MA
    Kamper, AM
    van Veen, S
    Souverijn, JHM
    Blauw, GJ
    NEPHROLOGY DIALYSIS TRANSPLANTATION, 2001, 16 (11) : 2152 - 2157
  • [40] Regional Variance of the Early Use of Tolvaptan for Autosomal Dominant Polycystic Kidney Disease
    Inoue, Reiko
    Nishi, Hiroshi
    Inoue, Daisuke
    Honda, Kenjiro
    Nangaku, Masaomi
    KIDNEY360, 2020, 1 (08): : 2020 - 745
12345